Bristol Myers Squibb Eyes Houston for $1 Billion Manufacturing Campus

Another pharmaceutical giant is setting its sights on Houston.

Bristol Myers Squibb (NYSE: BMY), one of the world's largest biopharmaceutical companies, has filed an application for a major tax incentive program in Texas — signaling that Houston is in serious contention for a $1 billion domestic manufacturing facility that could bring hundreds of jobs to the region.

The New Jersey-based drugmaker, operating through its subsidiary E.R. Squibb & Sons LLC, submitted a filing through the Texas Jobs, Energy, Technology and Innovation (JETI) program, which offers 10-year property tax abatements on school district taxes. If approved, the company would receive tax relief through the Sheldon Independent School District, as the proposed site falls within McCord Development's Generation Park Management District in northeast Houston.

WHAT'S BEING PROPOSED

The plans outline a 600,000-square-foot manufacturing campus representing approximately $1 billion in capital investment, to be deployed over a three-year period beginning in 2027. The project is expected to create nearly 500 jobs at the site.

The proposed Houston location sits along the Aqueduct Road corridor between Lake Houston Parkway and Garrett Road — southeast of McCord Development's headquarters on Assay Street — placing it squarely within Generation Park, a 4,200-acre master-planned development that has been aggressively positioning itself as Houston's emerging life sciences hub.

Bristol Myers Squibb has reportedly shortlisted 16 sites across three states, meaning Houston is competing for this investment — not guaranteed to receive it.

WHY HOUSTON?

Generation Park has been working to attract major pharmaceutical manufacturers to northeast Houston for several years, and the strategy appears to be gaining traction. Bristol Myers Squibb's interest follows several other high-profile pharma announcements tied to the region, signaling that Houston is building momentum as a legitimate destination for life sciences manufacturing.

For BMS, the decision will likely hinge on a combination of factors: site readiness, infrastructure and utility capacity, available skilled workforce, and the strength of the incentive package Texas can offer. The JETI program — which provides a decade of school district property tax relief — is one of the state's primary tools for attracting large industrial investments, and it has already been used to attract other pharmaceutical players to the area.

ABOUT BRISTOL MYERS SQUIBB

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular conditions, and immunological disorders. The company's portfolio includes blockbuster therapies such as Opdivo, Revlimid, and Eliquis — drugs that touch millions of patients worldwide each year.

A domestic manufacturing expansion of this scale aligns with broader industry trends: pharmaceutical companies have been under mounting pressure — from regulatory bodies, policymakers, and the public — to bring drug production back to U.S. soil and reduce reliance on overseas supply chains.

Sources: Houston Business Journal, KHOU 11, Hoodline. This article is for informational purposes only.